Home Entrepreneur Best biotech stocks to buy in April? 4 to watch on...

Best biotech stocks to buy in April? 4 to watch on Monday

April 24, 2021

6 minutes of reading

This story originally appeared on Stock market

Now is the time to invest in these biotech stocks?

Some Top biotechnology stocks has been performing exceptionally well in the stock market. One reason for this may be the fact that the world is still affected by COVID-19. As vaccination rollouts continue, these vaccine companies continue to reap the rewards. For example, Moderna (NASDAQ: MRNA) reported total revenue of $ 803 million in its latest financial numbers. We all know how important health care is and the pandemic just increases the value of the biotechnology industry. However, biotech stocks have always been known to be a high-risk and high-return investment. A positive or up-to-date clinical result can lead to an increase in stock value. But at the same time, a negative result or update could cause these stocks to plummet.

Using Alexion Pharmaceutical (NASDAQ: ALXN) and AstraZeneca (NASDAQ: AZN) For example. Last week, it was announced that the US Federal Trade Commission had authorized mergers between the two companies. Last December, both companies signed a definitive deal for AstraZeneca to acquire Alexion for $ 39 billion. The announcement caused Alexion’s shares to skyrocket by more than 30% in December. This acquisition will undoubtedly enhance the combined organization’s position in immunology.

However, there are still many challenges for investors to learn about biotech stocks and their growth potential. However, with proper research and due diligence, investors can make informed choices about which biotech stocks are worth betting on. With that in mind, you have this list Top biotech stocks to buy inside stock market next week?

Top biotech stocks to buy [Or Avoid] In April

Johnson & Johnson

Johnson & Johnson (JNJ) is involved in the research and development, manufacture and sale of a wide range of products in the healthcare sector. It works through its three segments; Consumer, Pharmaceutical and Medical Equipment. Recently, the company had a number of failures with its vaccines, causing a number of side effects. However, many regulators believe that the benefits continue to outweigh the risks. Despite the negative news surrounding the company, its share price does not appear to be affected. Furthermore, there is news that vaccine delivery will be resumed soon. Could this prompt JNJ stock to retest its all-time high?

On Wednesday, JNJ announced that the European Medicines Agency’s Pharmaceutical Alert Risk Assessment (EMA) (PRAC) has updated the vaccine guidelines. As recommended by the PRAC, the company will begin to deliver COVID-19 vaccine across Europe. Furthermore, JNJ is optimistic that it will fulfill its commitment to deliver 100 million doses in the US and 200 million doses across Europe.

On top of that, JNJ’s single-shot COVID-19 vaccine is expected to be imported to India to “fill and finishIn June or July. Filling and finishing is the last step in the manufacturing process to get the vaccine in a vial or syringe. So with the company going to resume its vaccine distribution soon, it should clear some suspicions among investors. Considering all of this, would you consider buying JNJ stock right now?

[Read More] 4 renewable energy reserves need to be monitored before May

Pfizer Inc

Next, we have a multinational pharmaceutical corporation, Pfizer. The company was the first coronavirus vaccine company to have an FDA-approved emergency vaccine candidate. As of April 22, 2021, more than 114 million doses of the Pfizer vaccine are in use in the United States. However, PFE shares have been trading sideways for the past year. This could also change as the company is constantly making new positive discoveries about vaccines.

biotechnology stocks to buy (PFE shares)

In March, the company announced positive results in a Phase 3 teen trial to study the coronavirus vaccine. Essentially, the company reported that the adolescent vaccine for teenagers aged 12 to 15 years demonstrated 100% efficacy and a strong antibody response. Could Pfizer be the first company to approve vaccines for teenagers? Your prediction is as good as mine.

On top of that, the company found that their vaccines were effective in preventing symptomatic and severe diseases in people with chronic illnesses. This analysis involved almost 1.4 million people by Israel’s largest healthcare provider. It goes without saying that this offers hope for investors and countries receiving the Pfizer vaccine. Besides, the company will also sign a contract this month to supply another 50 million doses of vaccine to Japan in September. This comes amid a sudden increase in the number of cases in Japan. In fact, the government is considering declaring a state of emergency for Tokyo and Osaka. With all of this in mind, would you consider becoming a PFE equity investor?

[Read More] Go to Vs Lucid Motors: Which electric car stocks are better bought?

Ocugen Inc

Next up, Ocugen. This is a company that has a tradition of focusing on the development of treatments for blindness. The company’s pipeline products include OCU400, a new gene therapy product candidate that restores the integrity and function of the retina in a variety of genetically diverse retinopathy. However, with the introduction of COVID-19, the opportunity for the company to enter the COVID-19 race appeared. Ocugen has been working relentlessly to promote the development of Covaxin candidate COVID-19 vaccine with partner Bharat Biotech. Shares of the company soared as high as 42.92% on Thursday. In less than six months, stocks have risen more than 3000%.

Top biotech stocks to watch (Stocks OCGN)

What could be the catalyst of this sudden spike? Through a partnership with Bharat Biotech, an Indian vaccine specialist, they hope to bring Covaxin to the United States. On Wednesday, their partner Bharat released interim results from a Phase 3 study. Analysis found the vaccine’s efficacy to be 78% for mild, moderate, and severe COVID-19 diseases. Additionally, the efficacy against severe COVID-19 disease was 100%, with the result of less hospitalization.

On top of that, the effect for asymptomatic patients is 70%. This will reduce transmission among Covaxin recipients. Considering these exciting new results, would you like to jump into the OCGN securities group?

[Read More] Are cyclic stocks worth investing in? 4 to consider

Regeneron Pharmaceuticals Inc

To compile the list, we have one of the leading biotechnology companies developing drugs for the treatment of serious diseases, Regeneron. With many FDA-approved products already in its portfolio along with a handful of candidates in the rollout, Regeneron has been proud of its decent returns over the past few years. However, the company’s shares have been trading sideways for the past year or so. This recent weakness could be a buying opportunity for investors considering the company’s growth potential.

biotechnology stocks to buy (shares registered)

Last Monday, the company provided positive data from a late-stage study of asymptomatic COVID-19 patients recently. The new phase 3 trial data shows that a single dose of Regeneron’s COVID-19 antibody cocktail was able to prevent symptoms in 81% of infected people.

On top of that, symptomatic people were able to resolve their symptoms, on average, two weeks faster than those taking a placebo. Financially, Regeneron is also in a good place. In the fiscal year ending December 31, 2020, the company’s revenue grew 8% to $ 8.5 billion. Additionally, its net income increased 66% to $ 3.51 billion. Therefore, will these new findings cause REGN shares to be bought for you?



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments